Follow
Dan Cojocari
Dan Cojocari
Verified email at amgen.com
Title
Cited by
Cited by
Year
A three-dimensional engineered tumour for spatial snapshot analysis of cell metabolism and phenotype in hypoxic gradients
D Rodenhizer, E Gaude, D Cojocari, R Mahadevan, C Frezza, ...
Nature materials 15 (2), 227-234, 2016
1432016
5-Azacitidine induces NOXA to prime AML cells for venetoclax-mediated apoptosis
S Jin, D Cojocari, JJ Purkal, R Popovic, NN Talaty, Y Xiao, LR Solomon, ...
Clinical Cancer Research 26 (13), 3371-3383, 2020
1272020
Targeting tumour hypoxia to prevent cancer metastasis. From biology, biosensing and technology to drug development: the METOXIA consortium
EO Pettersen, P Ebbesen, RG Gieling, KJ Williams, L Dubois, P Lambin, ...
Journal of enzyme inhibition and medicinal chemistry 30 (5), 689-721, 2015
1252015
PTP1B controls non-mitochondrial oxygen consumption by regulating RNF213 to promote tumour survival during hypoxia
RS Banh, C Iorio, R Marcotte, Y Xu, D Cojocari, AA Rahman, J Pawling, ...
Nature cell biology 18 (7), 803-813, 2016
1132016
AMPK regulates metabolism and survival in response to ionizing radiation
VE Zannella, D Cojocari, S Hilgendorf, RN Vellanki, S Chung, ...
Radiotherapy and Oncology 99 (3), 293-299, 2011
722011
The autophagy associated gene, ULK1, promotes tolerance to chronic and acute hypoxia
MBE Schaaf, D Cojocari, TG Keulers, B Jutten, MH Starmans, MC de Jong, ...
Radiotherapy and Oncology 108 (3), 529-534, 2013
572013
New small molecule inhibitors of UPR activation demonstrate that PERK, but not IRE1α signaling is essential for promoting adaptation and survival to hypoxia
D Cojocari, RN Vellanki, B Sit, D Uehling, M Koritzinsky, BG Wouters
Radiotherapy and Oncology 108 (3), 541-547, 2013
562013
Hematologic tumor cell resistance to the BCL-2 inhibitor venetoclax: a product of its microenvironment?
JD Leverson, D Cojocari
Frontiers in Oncology 8, 458, 2018
412018
Quantitative visualization of hypoxia and proliferation gradients within histological tissue sections
M Zaidi, F Fu, D Cojocari, TD McKee, BG Wouters
Frontiers in Bioengineering and Biotechnology 7, 397, 2019
382019
A three-dimensional engineered heterogeneous tumor model for assessing cellular environment and response
D Rodenhizer, T Dean, B Xu, D Cojocari, AP McGuigan
Nature protocols 13 (9), 1917-1957, 2018
382018
Development of TRACER: tissue roll for analysis of cellular environment and response
D Rodenhizer, D Cojocari, BG Wouters, AP McGuigan
Biofabrication 8 (4), 045008, 2016
342016
Combination of enasidenib and venetoclax shows superior anti-leukemic activity against IDH2 mutated AML in patient-derived xenograft models
S Cathelin, D Sharon, A Subedi, D Cojocari, DC Phillips, JD Leverson, ...
Blood, The Journal of the American Society of Hematology 132 (Supplement 1 …, 2018
302018
Pevonedistat and azacitidine upregulate NOXA (PMAIP1) to increase sensitivity to venetoclax in preclinical models of acute myeloid leukemia
D Cojocari, BN Smith, JJ Purkal, MP Arrate, JD Huska, Y Xiao, A Gorska, ...
Haematologica 107 (4), 825, 2022
242022
Enasidenib-induced differentiation promotes sensitivity to venetoclax in IDH2-mutated acute myeloid leukemia
S Cathelin, D Sharon, A Subedi, D Cojocari, DC Phillips, JD Leverson, ...
Leukemia 36 (3), 869-872, 2022
102022
Pevonedistat, a Nedd-8 activating enzyme inhibitor, upregulates NOXA to increase effectiveness of azacitidine and venetoclax in preclinical models of acute myelogenous leukemia
BN Smith, D Cojocari, JJ Purkal, M Arrate, HE Ramsey, JD Leverson, ...
Blood 134, 1380, 2019
42019
5-Azacytidine Induces NOXA and PUMA Expression to Prime AML Cells for Venetoclax-Mediated Apoptosis
D Cojocari, S Jin, JJ Purkal, R Popovic, NN Talaty, Y Xiao, LR Solomon, ...
Blood 132, 2644, 2018
42018
Oxygen metabolism and hypoxia tolerance in organoid models of pancreatic ductal adenocarcinoma
J Zhang, Q Liu, D Cojocari, M Zaidi, T McKee, N Radulovich, MS Tsao, ...
Cancer Research 78 (13_Supplement), 2443-2443, 2018
32018
Selective MCL-1 inhibitor ABBV-467 is efficacious in tumor models but is associated with cardiac troponin increases in patients
J Yuda, C Will, DC Phillips, L Abraham, C Alvey, A Avigdor, W Buck, ...
Communications Medicine 3 (1), 154, 2023
22023
Therapeutic targeting of tumour hypoxia through the unfolded protein response and autophagy pathways
D Cojocari
University of Toronto (Canada), 2017
12017
Abstract SY31-02: Determinants of hypoxia in pancreatic cancer and identification of ULK1 as a potential therapeutic target
J Zhang, D Cojocari, R Cairns, M Koritzinsky, BG Wouters
Cancer Research 83 (7_Supplement), SY31-02-SY31-02, 2023
2023
The system can't perform the operation now. Try again later.
Articles 1–20